BR112023021162A2 - Peptídeos imunogênicos de magec2, proteínas de ligação que reconhecem os peptídeos imunogênicos de magec2 e usos dos mesmos - Google Patents

Peptídeos imunogênicos de magec2, proteínas de ligação que reconhecem os peptídeos imunogênicos de magec2 e usos dos mesmos

Info

Publication number
BR112023021162A2
BR112023021162A2 BR112023021162A BR112023021162A BR112023021162A2 BR 112023021162 A2 BR112023021162 A2 BR 112023021162A2 BR 112023021162 A BR112023021162 A BR 112023021162A BR 112023021162 A BR112023021162 A BR 112023021162A BR 112023021162 A2 BR112023021162 A2 BR 112023021162A2
Authority
BR
Brazil
Prior art keywords
magec2
immunogenic peptides
recognize
binding proteins
immunogenic
Prior art date
Application number
BR112023021162A
Other languages
English (en)
Portuguese (pt)
Inventor
P Ferretti Andrew
Gavin Macbeath
Qikai Xu
Yifan Wang
Original Assignee
Academisch Ziekenhuis Leiden
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden, Tscan Therapeutics Inc filed Critical Academisch Ziekenhuis Leiden
Publication of BR112023021162A2 publication Critical patent/BR112023021162A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
BR112023021162A 2021-04-14 2022-04-14 Peptídeos imunogênicos de magec2, proteínas de ligação que reconhecem os peptídeos imunogênicos de magec2 e usos dos mesmos BR112023021162A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163174808P 2021-04-14 2021-04-14
US202263329523P 2022-04-11 2022-04-11
PCT/US2022/024728 WO2022221479A2 (en) 2021-04-14 2022-04-14 Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof

Publications (1)

Publication Number Publication Date
BR112023021162A2 true BR112023021162A2 (pt) 2024-01-16

Family

ID=83641016

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021162A BR112023021162A2 (pt) 2021-04-14 2022-04-14 Peptídeos imunogênicos de magec2, proteínas de ligação que reconhecem os peptídeos imunogênicos de magec2 e usos dos mesmos

Country Status (11)

Country Link
US (1) US20240190931A1 (https=)
EP (1) EP4323379A4 (https=)
JP (1) JP2024515646A (https=)
KR (1) KR20240007162A (https=)
AU (1) AU2022256469A1 (https=)
BR (1) BR112023021162A2 (https=)
CA (1) CA3216553A1 (https=)
IL (1) IL307601A (https=)
MX (1) MX2023012141A (https=)
TW (1) TW202304964A (https=)
WO (1) WO2022221479A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820429B (zh) * 2024-01-11 2024-06-18 中国水产科学研究院南海水产研究所 一种具有inos抑制作用的乌鳢源活性肽
AU2025202443A1 (en) * 2024-04-08 2025-10-23 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
CN120098931A (zh) * 2025-02-10 2025-06-06 武建强 具有杀伤和肿瘤抑制功效的tcr-t细胞及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
GB201520539D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN119930795A (zh) * 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
CN112004825A (zh) * 2018-02-12 2020-11-27 弗雷德哈钦森癌症研究中心 细胞周期蛋白a1特异性t细胞受体及其用途
CN112368386A (zh) * 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 共有抗原
CN112888707B (zh) * 2018-08-16 2025-04-25 百欧恩泰美国公司 T细胞受体构建体及其用途
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
SG11202103609YA (en) * 2018-10-25 2021-05-28 Council Queensland Inst Medical Res T-cell receptors and uses thereof
EP3917542A4 (en) * 2019-01-29 2023-03-08 Gritstone bio, Inc. MULTISPECIFIC BINDING PROTEINS

Also Published As

Publication number Publication date
KR20240007162A (ko) 2024-01-16
WO2022221479A3 (en) 2022-11-24
EP4323379A4 (en) 2025-12-17
IL307601A (en) 2023-12-01
AU2022256469A1 (en) 2023-10-12
TW202304964A (zh) 2023-02-01
EP4323379A2 (en) 2024-02-21
US20240190931A1 (en) 2024-06-13
WO2022221479A2 (en) 2022-10-20
CA3216553A1 (en) 2022-10-20
JP2024515646A (ja) 2024-04-10
MX2023012141A (es) 2023-11-28

Similar Documents

Publication Publication Date Title
BR112023021162A2 (pt) Peptídeos imunogênicos de magec2, proteínas de ligação que reconhecem os peptídeos imunogênicos de magec2 e usos dos mesmos
BR112023021034A2 (pt) Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
CY1122494T1 (el) Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
CO2018009533A2 (es) Conjugados de amanitina
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
SA520420332B1 (ar) الأجسام المضادة لمكون مضاد للمتمم وطرق استخدامها
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
MA41669A1 (fr) Anticorps se liant a tau
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
CU20170169A7 (es) Anticuerpos de factor xi
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
BR112023023671A2 (pt) Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
BR112023015050A2 (pt) Anticorpos anti-met e usos dos mesmos
CO2024007212A2 (es) Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos
BR112022005465A2 (pt) Conjugados de proteína-macromolécula e métodos de uso dos mesmos
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 63/174,808 E US 63/329,523 REIVINDICADA NO PCT/US2022/024728 POR NAO APRESENTACAO DO CORRESPONDENTE DOCUMENTO DE CESSAO NO PRAZO LEGAL DE 60 DIAS APOS A PETICAO DE ENTRADA NA FASE NACIONAL DO BRASIL CONFORME AS DISPOSICOES PREVISTAS NO ART. 16 6O DA LEI 9.279 DE 14/05/1996 (LPI) E ART 19 2O DA PORTARIA INPI 39 DE 23/08/2021, UMA VEZ QUE OS DEPOSITANTES CONSTANTES DA PETICAO DE REQUERIMENTO DO PEDIDO PCT SAO DISTINTOS DAQUELES QUE DEPOSITARAM AS PRIORIDADES REIVINDICADAS.

B12F Other appeals [chapter 12.6 patent gazette]

Free format text: RECURSO: 870240023770 - 19/3/2024